SAB Biotherapeutics

SABS · NASDAQ

$2.88+$0.28 (+10.77%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.60

Latest news

Press releaseOct 13, 8:30 AM ETGlobe Newswire
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Press releaseAug 6, 7:30 AM ETGlobe Newswire
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Press releaseJul 30, 8:30 AM ETGlobe Newswire
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
NewsMay 12, 8:59 AM ET
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call
Press releaseMay 12, 7:30 AM ETGlobe Newswire
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
NewsMay 12, 7:11 AM ET
Earnings Scheduled For May 12, 2026
Press releaseMay 5, 8:30 AM ETGlobe Newswire
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
NewsApr 29, 7:38 AM ET
Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes
Press releaseApr 29, 7:35 AM ETGlobe Newswire
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
Press releaseApr 22, 7:00 AM ETGlobe Newswire
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
Press releaseMar 19, 4:01 PM ETGlobe Newswire
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Press releaseMar 17, 10:46 PM ETGlobe Newswire
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
NewsMar 17, 4:03 PM ET
SAB Biotherapeutics Launches Public Stock Offering To Fund Development Of Type 1 Diabetes Therapy; No Terms Disclosed
Press releaseMar 17, 4:01 PM ETGlobe Newswire
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NewsDec 8, 4:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsSep 23, 5:07 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsSep 3, 8:08 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMay 21, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseJan 31, 7:00 AM ETGlobe Newswire
SAB BIO to Participate in Upcoming Investor Conferences
NewsJan 28, 3:40 PM ETVandana Singh
Why Is SAB BIO Stock Trading Lower On Tuesday?
NewsJan 28, 1:46 PM ETAvi Kapoor
Gold Gains 1%; Boeing Shares Rise Following Q4 Results
NewsJan 28, 12:20 PM ETAvi Kapoor
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results
NewsJan 28, 9:44 AM ETAvi Kapoor
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings
Press releaseOct 31, 7:00 AM ETGlobe Newswire
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Press releaseSep 13, 7:00 AM ETGlobe Newswire
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Earnings Scheduled For May 12, 2026

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB Biotherapeutics Launches Public Stock Offering To Fund Development Of Type 1 Diabetes Therapy; No Terms Disclosed

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

SAB BIO to Participate in Upcoming Investor Conferences

Why Is SAB BIO Stock Trading Lower On Tuesday?

Gold Gains 1%; Boeing Shares Rise Following Q4 Results

Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results

Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference